Related Experiment Video
Updated: Jan 22, 2026

Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
Norepinephrine-Transporter-Targeted and DNA-Co-Targeted Theranostic Guanidines
Zbigniew P Kortylewicz1, Donald W Coulter2, Guang Han1,3
1Department of Radiation Oncology, J. Bruce Henriksen Cancer Research Laboratories, University of Nebraska Medical Center, Omaha, Nebraska 68132-6850, United States.
Abstract:
High risk neuroblastoma often recurs, even with aggressive treatments. Clinical evidence suggests that proliferative activities are predictive of poor outcomes. This report describes syntheses, characterization, and biological properties of theranostic guanidines that target norepinephrine transporter and undergo intracellular processing, and subsequently their catabolites are efficiently incorporated into DNA of proliferating neuroblastoma cells. Radioactive guanidines are synthesized from 5-radioiodo-2'-deoxyuridine, a molecular radiotherapy platform with clinically proven minimal toxicities and DNA-targeting properties. The transport of radioactive guanidines into neuroblastoma cells is active as indicated by the competitive suppression of cellular uptake by meta-iodobenzylguanidine. The rate of intracellular processing and DNA uptake is influenced by the agent's catabolic stability and cell population doubling times. The radiotoxicity is directly proportional to DNA uptake and duration of exposure. Biodistribution of 5-[125I]iodo-3'-O-(ε-guanidinohexanoyl)-2'-deoxyuridine in a mouse neuroblastoma model shows significant tumor retention of radioactivity. Neuroblastoma xenografts regress in response to the clinically achievable doses of this agent.
Insights
New theranostic guanidines target neuroblastoma cells, incorporating into DNA and causing tumor regression. This DNA-targeting approach offers a promising new treatment for high-risk neuroblastoma, showing significant tumor retention and regression in preclinical models.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Biology
Background:
- High-risk neuroblastoma frequently recurs despite intensive therapies.
- Cellular proliferation is a key indicator of poor prognosis in neuroblastoma.
- Novel therapeutic strategies are needed to overcome treatment resistance.
Purpose of the Study:
- To synthesize and characterize novel theranostic guanidines for neuroblastoma.
- To evaluate the DNA-targeting and therapeutic potential of these agents.
- To assess the efficacy of guanidine-based radiopharmaceuticals in preclinical neuroblastoma models.
Main Methods:
- Synthesis and characterization of novel guanidine compounds.
- Assessment of cellular uptake and DNA incorporation in neuroblastoma cells.
- In vivo biodistribution and efficacy studies in a mouse neuroblastoma xenograft model.
- Evaluation of radiotoxicity correlated with DNA uptake and exposure duration.
Main Results:
- Theranostic guanidines were successfully synthesized and characterized.
- Active transport of guanidines into neuroblastoma cells was confirmed, with competitive inhibition observed.
- Radioiodinated guanidines demonstrated efficient intracellular processing and DNA incorporation.
- Significant tumor retention of radioactivity and regression of neuroblastoma xenografts were observed.
- Radiotoxicity was directly proportional to DNA uptake and exposure time.
Conclusions:
- Novel theranostic guanidines effectively target neuroblastoma cells via norepinephrine transporter.
- These agents are incorporated into the DNA of proliferating neuroblastoma cells, leading to radiotoxicity.
- Preclinical studies demonstrate significant tumor regression, supporting their potential as a new therapeutic option for high-risk neuroblastoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
DNA-only Transposons
The donor site from where the transposon is excised is either degraded or...
Regulated mRNA Transport
Facilitated Transport

